Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”) Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”) Further development of Sollpura to be discontinued Anthera to evaluate all strategic alternatives Anthera to host
View HTML
Toggle Summary Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference
HAYWARD, Calif. , March 07, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal
View HTML
Toggle Summary Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria
HAYWARD, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals  (Nasdaq:ANTH) today announced that Anthera has received formal notice from The NASDAQ Stock Market LLC (“Nasdaq”) indicating that the Company has evidenced full compliance with all requirements for continued listing on
View HTML
Toggle Summary Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results
RESULT study reported positive interim futility analyses and completion of dosing, with top line data expected in March 2018 Completed private placement for net proceeds of $13.3 million Received net proceeds of $3.1 million from warrant exercises and sale of shares pursuant to an equity purchase
View HTML
Toggle Summary Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orphan Drug Day
HAYWARD, Calif. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal
View HTML
Toggle Summary Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
HAYWARD, Calif. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) is pleased to announce that the final patient has completed the last visit in the primary treatment phase of RESULT, a Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency (“EPI”)
View HTML
Toggle Summary Anthera Receives Positive Nasdaq Listing Determination
HAYWARD, Calif. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that on January 24, 2018 , Anthera received formal notice that the Nasdaq Hearings Panel granted Anthera’s request for inclusion on The Nasdaq Capital Market .
View HTML
Toggle Summary Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter
HAYWARD, Calif. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency (“EPI”).
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
HAYWARD, Calif. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) today announced that it has completed the second closing of the private placement of its equity securities (“PIPE”) with certain institutional and accredited investors.  The PIPE transaction was
View HTML
Toggle Summary Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
HAYWARD, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals , Inc. (Nasdaq:ANTH) is pleased to announce the results of the Special Meeting of Stockholders held on January 5 , 2018.  Shareholders approved all of the proposed business matters which included: (i) approval of the second
View HTML